Get started
Author

Ibrahim Qazi

Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark
2017 · Vera Ehrenstein, Søren L. Andersen, et al. · The Journal of Rheumatology · 103
A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).
2017 · Kamalesh Kumar Sankhala, Jean-Yves Blay, et al. · Journal of Clinical Oncology · 44
Interventions to Increase Osteoporosis Treatment in Patients with ‘Incidentally’ Detected Vertebral Fractures
2012 · Sumit R. Majumdar, Finlay A. McAlister, et al. · The American Journal of Medicine · 39
A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
2021 · Elizabeth Budde, Ajay K Gopal, et al. · Blood · 31
The Clinical Landscape of Antibody-drug Conjugates
2014 · Sohayla Rostami, Ibrahim Qazi, et al. · ADC Review / Journal of Antibody-drug Conjugates · 15
Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
2022 · Genevive H. Hernandez, John So, et al. · Blood · 12
Abstract B143: A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers
2016 · Julie Brahmer, Drew Rasco, et al. · Cancer Immunology Research · 9
A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).
2019 · Jian-Ming Xu, Ken Kato, et al. · Journal of Clinical Oncology · 3
PR031/#1199 Phase I, two-part, mutlicenter, first-in-human (FIH) study of TORL-1–23, a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patients with advanced solid tumors
2024 · Gottfried Konecny, Andrea Wahner Hendrickson, et al. · International Journal of Gynecological Cancer · 2
PDF
Abstract CT052: A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas
2023 · Catherine Diefenbach, Won Seog Kim, et al. · Cancer Research · 1
Abstract CT125: A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas
2022 · Loretta Nastoupil, Elizabeth Budde, et al. · Cancer Research · 1
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.
2020 · Harry H. Yoon, Ken Kato, et al. · Journal of Clinical Oncology
Works count: 13
Citation count: 261
H-index: 7
I10-index: 6
Year
Topic
Type